Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

BACKGROUND: ALK gene rearrangement defines a new molecular subtype of non-small-cell lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK tyrosine-kinase inhibitor (TKI) crizotinib showed marked antitumour activity in patients with advanced, ALK-positive NSCLC. To assess whether crizotin...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Shaw, Alice T, Yeap, Beow Y, Solomon, Benjamin J, Riely, Gregory J, Gainor, Justin, Engelman, Jeffrey A, Shapiro, Geoffrey I, Costa, Daniel B, Ou, Sai-Hong I, Butaney, Mohit, Salgia, Ravi, Maki, Robert G, Varella-Garcia, Marileila, Doebele, Robert C, Bang, Yung-Jue, Kulig, Kimary, Selaru, Paulina, Tang, Yiyun, Wilner, Keith D, Kwak, Eunice L, Clark, Jeffrey W, Iafrate, A John, Camidge, D Ross
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3328296/
https://ncbi.nlm.nih.gov/pubmed/21933749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70232-7
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak